poisar

Stock

Tenaya Therapeutics, Inc. TNYA

$0.70+0.01%

Overview

TNYA market data

Price History

TNYA price chart · 3M
O
0.702500
H
0.713700
L
0.698400
C
0.700100
Vol
21,983.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$0.70
Previous Close
$0.70
Day High
$0.71
Day Low
$0.70
52 Week High
$1.15
52 Week Low
$0.66
7 Day Return
+1.35%
30 Day Return
-7.15%
90 Day Return
-20.59%
1 Year Return
+5.56%
Daily Notional Volume
$15.4K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.59
Diluted earnings per share over the trailing twelve months.
Beta
2.94
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$0.53 – $2.35
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $164.4M · P/B 1.25.

Company News

4 captured
Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M EstimateBenzinga · Aug 5, 2026, 10:39 PM
8-K filing — Tenaya Therapeutics, Inc. (TNYA)SEC EDGAR · Jul 2, 2026, 9:00 PM
Tenaya Therapeutics Appoints Eric Hyllengren CFO, Effective July 13Benzinga · Jun 29, 2026, 12:40 PM
Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3Benzinga · Jun 2, 2026, 8:32 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock